Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells

Cancer Gene Therapy

Volumn 20, Issue 1, 2013, Pages 33-37

  Lu, T ^a   Shao, N ^a   Ji, C ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

microRNA; TRAIL

Indexed keywords

MICRORNA; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; CELL TYPE; CYTOTOXICITY; GENE TARGETING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84871981322     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.81     Document Type: Review

References (71)

1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science 2003; 301: 336-338.
3. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-4060.
4. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10: 1957-1966.
5. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432: 231-235.
6. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004; 303: 95-98.
7. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of premicroRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011-3016.
8. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293: 834-838.
9. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
10. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
11. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
12. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 2011; 121: 361-366.
13. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
14. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
15. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
16. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430.
17. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
18. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
19. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
20. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475.
21. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055.
22. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11: 17-24.
23. Koehler BC, Urbanik T, Vick B, Boger RJ, Heeger S, Galle PR et al. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15: 5924-5935.
24. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur J Pharmacol 2009; 625: 63-72.
25. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27: 3845-3855.
26. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16: 498-509.
27. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086.
28. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102: 19075-19080.
29. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108: 3068-3071.
30. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-3708.
31. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012; 31: 634-642.
32. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404-410.
33. Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 2008; 15: 427-434.
34. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 2010; 70: 3638-3646.
35. Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, Andreozzi F et al. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 1998; 17: 3858-3866.
36. Renault F, Formstecher E, Callebaut I, Junier MP, Chneiweiss H. The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem Pharmacol 2003; 66: 1581-1588.
37. Condorelli G, Vigliotta G, Cafieri A, Trencia A, Andalo P, Oriente F et al. PED/PEA-15: An anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999; 18: 4409-4415.
38. Zanca C, Garofalo M, Quintavalle C, Romano G, Acunzo M, Ragno P et al. PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. J Cell Mol Med 2008; 12: 2416-2426.
39. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75(1 Suppl): 171-190.
40. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798.
41. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: From DNA methylation to microRNAs. World J Gastroenterol 2007; 13: 6465-6469.
42. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100: 1234-1242.
43. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 2007; 619: 30-37.
44. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012; 55: 465-475.
45. Thomas LW, Lam C, Edwards SW. Mcl-1: The molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989.
46. Mott JL, Kobayashi S, Bronk SF, Gores GJ. miR-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140.
47. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-3524.
48. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661.
49. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97-117.
50. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
51. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033.
52. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. Micro-RNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007; 67: 8994-9000.
53. Walter J, Honsek SD, Illes S, Wellen JM, Hartung HP, Rose CR et al. A new role for interferon gamma in neural stem/precursor cell dysregulation. Mol Neurodegener 2011; 6: 18.
54. Visted T, Enger PO, Lund-Johansen M, Bjerkvig R. Mechanisms of tumor cell invasion and angiogenesis in the central nervous system. Front Biosci 2003; 8: E289-e304.
55. Simpson L, Galanis E. Recurrent glioblastoma multiforme: Advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 2006; 6: 1593-1607.
56. Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004; 64: 3236-3242.
57. Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 2005; 57: 34-41.
58. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAILinduced apoptosis pathway. Cancer Res 2007; 67: 10782-10788.
59. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 2003; 426: 247-254.
60. Ozaki H, Nakamura K, Funahashi J, Ikeda K, Yamada G, Tokano H et al. Six1 controls patterning of the mouse otic vesicle. Development 2004; 131: 551-562.
61. Xu PX, Zheng W, Huang L, Maire P, Laclef C, Silvius D. Six1 is required for the early organogenesis of mammalian kidney. Development 2003; 130: 3085-3094.
62. Zheng W, Huang L, Wei ZB, Silvius D, Tang B, Xu PX. The role of Six1 in mammalian auditory system development. Development 2003; 130: 3989-4000.
63. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA 2004; 101: 6478-6483.
64. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1as key metastatic regulators. Nat Med 2004; 10: 175-181.
65. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010; 29: 4971-4979.
66. Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007; 67: 3036-3042.
67. Lu Q, Lu C, Zhou GP, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol 2010; 28: 635-641.
68. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103: 256-264.
69. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
70. Patron JP, Fendler A, Bild M, Jung U, Muller H, Arntzen MO et al. MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 2012; 7: E35345.
71. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11: 17-24.